Research Radartracking 4 published studies · 1 human · 2 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “ovarian cancer”.
1 of 4 studies
ReviewInconclusiveLimited evidenceTier 4 · clinical

Frontiers of Ovarian Carcinosarcoma

Current treatment options in oncology · Dec 2023 · narrative review

ovarian carcinosarcomaovarian cancer

This review summarizes what is known about ovarian carcinosarcoma, a rare and aggressive ovarian cancer. It discusses risk factors, prognostic markers, and current treatment approaches such as surgery followed by platinum-based chemotherapy, while noting that immunotherapy and HRD testing may be useful in some patients. The article does not report new experimental results from a trial or laboratory study.

Key findings
  • Ovarian carcinosarcoma is described as rare and aggressive, with median overall survival under 2 years.
  • Poor prognostic factors include advanced stage, older age, lymph node metastasis, suboptimal cytoreduction, heterologous histology, and increased VEGF, p53, and WT1 expression.
  • Main treatment approach is cytoreductive surgery followed by platinum-based chemotherapy.
  • Immunotherapy is described as promising, and HRD testing may help personalize therapy.
Limitations: Narrative review rather than original research.; No new patient cohort, control group, or quantitative treatment effect data reported in the abstract.; Most evidence discussed is from case reports and small studies.; The abstract does not specify which therapies or biomarkers were evaluated in detail..

Provides an overview of ovarian carcinosarcoma epidemiology, prognosis, and treatment options rather than testing a specific compound.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text